Jujuboside B

Jujuboside B
Product Name Jujuboside B
CAS No.: 55466-05-2
Catalog No.: CFN98102
Molecular Formula: C52H84O21
Molecular Weight: 1045.22 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: White powder
Targets: Caspase | JNK | p38MAPK | Autophagy | NO | NOS | Calcium Channel
Source: The seeds of Ziziphus jujuba
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $80/20mg
Jujuboside B has antitumor activity and the underlying mechanism via induction of apoptosis and autophagy. It reduces vascular tension endothelium-dependently by increasing Ca2+Influx and activating endothelial nitric oxide synthase, it has pharmacological effects on improving endothelial dysfunction and treating vascular diseases.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • CZECH MYCOLOGY2021, 73(1):1-19.
  • J Health Sci Med Res.2023, 31584.
  • Pharmaceuticals (Basel).2020, 13(9):262.
  • Sci Rep.2019, 9(1):4342
  • FEMS Microbiol Lett.2017, 364(11)
  • ACS Synth Biol.2020, 9(9):2282-2290.
  • TCI CO.2019, US20190151281A1
  • Korean J. Medicinal Crop Sci.2022, 30(2):117-123.
  • Malaysian Journal of Analytical Sciences2023, 27(4):840-848.
  • J-STAGE2015, 249-255
  • Jujuboside B

    Catalog No: CFN98102
    CAS No: 55466-05-2
    Price: $80/20mg
    Jujuboside A

    Catalog No: CFN98101
    CAS No: 55466-04-1
    Price: $70/20mg
    Jujuboside D

    Catalog No: CFN98103
    CAS No: 194851-84-8
    Price: $360/10mg
    PLoS One. 2016 Feb 22;11(2):e0149386.
    Jujuboside B Reduces Vascular Tension by Increasing Ca2+ Influx and Activating Endothelial Nitric Oxide Synthase.[Pubmed: 26901291 ]
    Jujuboside B has been reported to have protective effect on many cardiovascular diseases. However, the effects of Jujuboside B on vascular tension and endothelial function are unknown. The present study investigated the effects of Jujuboside B on reducing vascular tension, protecting endothelial function and the potential mechanisms.
    METHODS AND RESULTS:
    The tension of isolated rat thoracic aorta ring was measured by Wire myograph system. The concentration of nitric oxide (NO) and the activity of endothelial nitric oxide synthase (eNOS) in human aortic endothelial cells (HAECs) were determined by Griess reagent method and enzyme-linked immune sorbent assay. The protein levels of eNOS and p-eNOS at Serine-1177 were determined by western blot analysis. Intracellular Ca2+ concentration in HAECs was measured by laser confocal imaging microscopy. Results showed that Jujuboside B reduced the tension of rat thoracic aorta rings with intact endothelium in a dose-dependent manner. L-NAME, KN93, EGTA, SKF96365, iberiotoxin and glibenclamide significantly attenuated Jujuboside B-induced vasodilation in endothelium-intact tissues. In contrast, indometacin and 4-DAMP had no such effects. Jujuboside B also promoted NO generation and increased eNOS activity, which were attenuated by L-NAME, EGTA and SKF96365. Moreover, Jujuboside B increased intracellular Ca2+ concentration dose-dependently, which was inhibited by EGTA and SKF96365. Besides, Jujuboside B induced a rapid Ca2+ influx instantaneously after depleting intracellular Ca2+ store, which was significantly inhibited by SKF96365.
    CONCLUSIONS:
    In conclusion, this study preliminarily confirmed that Jujuboside B reduced vascular tension endothelium-dependently. The underlying mechanisms involved that Jujuboside B increased extracellular Ca2+ influx through endothelial transient receptor potential cation (TRPC) channels, phosphorylated eNOS and promoted NO generation in vascular endothelial cells. In addition, Jujuboside B-induced vasodilation involved endothelium-dependent hyperpolarizaiton through endothelial potassium channels. Jujuboside B is a natural compound with new pharmacological effects on improving endothelial dysfunction and treating vascular diseases.
    Phytother Res. 2013 Jun;27(6):829-34.
    Zizyphus jujuba and its active component jujuboside B inhibit platelet aggregation.[Pubmed: 22893618]
    The seeds of Zizyphus jujuba (SZJ), a famous oriental traditional medicine, have been reported to exhibit diverse activities in biological systems including the cardiovascular system. However, little information is available on its antiplatelet activity. This study was undertaken to investigate the antiplatelet effects of the ethanolic extract of SZJ (ESZJ) and of its principal components jujuboside A and Jujuboside B.
    METHODS AND RESULTS:
    In the in vitro platelet aggregation study, ESZJ exhibited significant and concentration-dependent inhibitory effects on collagen-, thrombin-, and AA-induced platelet aggregation. In addition, ESZJ-treated mice showed significantly the prolongation of bleeding times and the protection against thromboembolic attack. A comparison of the effects of jujuboside A and Jujuboside B on platelet aggregation revealed that only Jujuboside B had potent inhibitory effects on collagen-, thrombin-, AA-, and ADP-induced aggregation. Jujuboside B also exhibited superior protection on thromboembolic model. Furthermore, Jujuboside B had a significant inhibitory effect on collagen-induced thromboxane A2 production in rat platelets.
    CONCLUSIONS:
    This study describes the antiplatelet effects of ESZJ and of its active component Jujuboside B, and its findings suggest that these agents be considered as components of preventive and therapeutic herbal drugs targeting cardiovascular diseases associated with platelet hyperaggregation.
    J Nat Prod. 2014 Feb 28;77(2):370-6.
    Antitumor activity of jujuboside B and the underlying mechanism via induction of apoptosis and autophagy.[Pubmed: 24547878]
    Jujuboside B (1) is one of the saponins isolated from the seeds of Zizyphus jujuba var. spinosa, which are used as a well-known traditional medicine for the treatment of insomnia and anxiety in East Asian countries. This is the first study to investigate the antitumor mechanism of 1 in vivo and in vitro.
    METHODS AND RESULTS:
    The results showed that 1 induced apoptosis and autophagy in AGS and HCT 116 human cancer cells and also effectively suppressed tumor growth in a nude mouse xenograft model bearing HCT 116 cells. The apoptosis-inducing effect of 1 was characterized by annexin V/propidium iodide staining, sub-G1 phase increase, and caspase-3 activation. Mechanistic studies showed that 1-induced apoptosis is associated with the extrinsic pathway through an increase in FasL and caspase-8 activation. Moreover, 1 activated p38/c-Jun N-terminal kinase (JNK), and the extrinsic pathway-mediated apoptosis was attenuated by both SB202190 (a p38 inhibitor) and SP600125 (a JNK inhibitor). The autophagy-inducing effect was indicated by the formation of cytoplasmic vacuoles and microtubule-associated protein 1 light chain-3 II (LC3-II) conversion. The autophagy inhibitor bafilomycin A1 (BaF) decreased 1-induced cell viability and increased pp38, pJNK, FasL, caspase-8 activation, and caspase-3 activation.
    CONCLUSIONS:
    Taken together, these results demonstrate that 1 induced protective autophagy to retard extrinsic pathway-mediated apoptosis.
    Selaginellin F

    Catalog No: CFN95029
    CAS No: 1340493-24-4
    Price: $413/5mg
    Silychristin B

    Catalog No: CFN95160
    CAS No: 879325-58-3
    Price: $318/5mg
    Pterodonoic acid

    Catalog No: CFN95183
    CAS No: 62458-42-8
    Price: $413/5mg
    2-Methoxy-5-acetoxy-furanogermacr-1(10)-en-6-one

    Catalog No: CFN95197
    CAS No: 1809980-25-3
    Price: $318/10mg
    N-trans-caffeoyltyramine

    Catalog No: CFN95265
    CAS No: 103188-48-3
    Price: $318/5mg
    New compound 12 (Rhoifolin analog)

    Catalog No: CFN95371
    CAS No: N/A
    Price: $318/5mg
    Oblonganoside D

    Catalog No: CFN95460
    CAS No: 943021-91-8
    Price: $318/5mg
    Ganoderic acid Df

    Catalog No: CFN95514
    CAS No: 1352033-73-8
    Price: $318/5mg
    Catechin 7-O-beta-D-glucopyranoside

    Catalog No: CFN95524
    CAS No: 65597-47-9
    Price: $338/20mg
    Mahuannin B

    Catalog No: CFN95554
    CAS No: 82796-37-0
    Price: $318/5mg